HBV Treatment
HBeAg Decrease during Treatment Predicts Sustained Response to Pegylated Interferon for Chronic Hepatitis B
- Details
- Category: HBV Treatment
- Published on Friday, 04 June 2010 12:49
- Written by Liz Highleyman
Levels of hepatitis B "e" antigen (HBeAg) during treatment may be a more accurate predictor than hepatitis B surface antigen (HBsAg) or HBV viral load for determining which patients will respond to pegylated interferon for chronic hepatitis B, according to a study from Thailand published in the March 2010 issue of Hepatology Research.
EASL 2010: Spontaneous Undetectable Hepatitis B Virus DNA Is Uncommon, especially without HBeAg Clearance
- Details
- Category: HBV Treatment
- Published on Friday, 14 May 2010 19:17
- Written by Liz Highleyman
Clearance of hepatitis B virus (HBV) DNA from the blood seldom occurs without treatment even after a decade, researchers reported at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. Among people who experience hepatitis B "e" antigen (HBeAg) clearance, however, the likelihood of also achieving undetectable viral load was higher, approaching 50% at 10 years.
EASL 2010: Tenofovir (Viread) Effective for Treatment of Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (Hepsera)
- Details
- Category: HBV Treatment
- Published on Tuesday, 04 May 2010 12:56
- Written by Liz Highleyman
Treatment with tenofovir (Viread) monotherapy for up to 96 weeks produced complete suppression of hepatitis B virus (HBV) in patients who had detectable viral load using the related nucleotide analog adefovir (Hepsera), according to data from a pooled analysis presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. In addition, tenofovir was well tolerated and no drug resistance was observed.
Longer Treatment with Pegylated Interferon Works Better for Hepatitis B Genotype D
- Details
- Category: HBV Treatment
- Published on Friday, 07 May 2010 12:56
- Written by Liz Highleyman
HBeAg negative people with hepatitis B virus (HBV) genotype D doubled their rate of sustained response when treated with pegylated interferon for 2 years instead of 1 year, and HBsAg clearance was also more likely with longer therapy, according to study results presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna
EASL 2010: HBV DNA and HBsAg Levels Predict Likelihood of Sustained Response to Pegylated Interferon for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 27 April 2010 12:55
- Written by Liz Highleyman
Decreases in levels of hepatitis B virus (HBV) DNA and hepatitis B surface antigen (HBsAg) while receiving treatment with pegylated interferon can help predict which hepatitis B "e" antigen (HBeAg) negative patients will ultimately achieve a sustained response, according to presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) this month in Vienna. Investigators recommended that people who do not experience adequate decreases in these levels by week 12 should discontinue therapy.
More Articles...
- EASL 2010: Tenofovir (Viread) Demonstrates High Barrier to Resistance over 3 Years in Chronic Hepatitis B Patients
- EASL 2010: Tenofovir/emtricitabine (Truvada) Prevents Hepatitis B Recurrence after Liver Transplantation in Patients with Mild Kidney Impairment
- Traditional Chinese Medicine May Perform Better than Interferon or Lamivudine for Chronic Hepatitis B
- Entecavir (Baraclude) Works Well in Patients with Adefovir-resistant Hepatitis B, but Lamivudine Resistance Compromises Efficacy
Web Design and Development by